megestrol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   26 Trials   26 Trials   791 News 


«12345678910»
  • ||||||||||  ibuprofen / generics
    Journal:  Presence of emerging contaminants in urban water bodies in southern Brazil. (Pubmed Central) -  Jun 6, 2019   
    Ibuprofen and paracetamol were detected in several samples, while diclofenac was absent. The mean concentration of ibuprofen in the João Goulart catchment was 0.51 μg L and in the Cancela-Tamandaí it was 1.26 μg L. Mean paracetamol concentrations were 0.4 μg L in the João Goulart catchment and 3.0 μg L in the Cancela-Tamandaí.
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment open, Metastases:  Randomized Control Trial (RCT) of Early Palliative Care for HCC (clinicaltrials.gov) -  Apr 22, 2019   
    P=N/A,  N=72, Recruiting, 
    The mean concentration of ibuprofen in the João Goulart catchment was 0.51 μg L and in the Cancela-Tamandaí it was 1.26 μg L. Mean paracetamol concentrations were 0.4 μg L in the João Goulart catchment and 3.0 μg L in the Cancela-Tamandaí. Not yet recruiting --> Recruiting
  • ||||||||||  Megace (megestrol) / BMS
    Clinical, Journal:  Clinical Inquiry: Is megestrol acetate safe and effective for malnourished nursing home residents? (Pubmed Central) -  Apr 14, 2019   
    After 44 months, however, MA-treated patients showed decreased median survival (SOR: B, single case-control study). Consistent, meaningful weight gain was not observed with MA treatment (SOR: B, single case-control study, single RCT, 2 retrospective chart reviews, single prospective case-series).
  • ||||||||||  3-day fentanyl transdermal patcht / Generic mfg., megestrol / Generic mfg., Avastin (bevacizumab) / Roche
    Clinical, Review, Journal:  Paraneoplastic Encephalopathy in a Patient With Metastatic Lung Cancer: A Case Study. (Pubmed Central) -  Dec 28, 2018   
    According to her husband, RS was diagnosed with stage IIIA large cell lung cancer 8 months earlier and was treated with concurrent chemotherapy (carboplatin, pemetrexed, and bevacizumab) and radiation therapy that was completed 4 months prior to admission...Home medications included transdermal fentanyl 12 μg/hr patch changed every 72 hours; oxycodone-acetaminophen tablets 5-325 mg, two every 4 hours as needed for pain; prednisone 10 mg, one tablet daily; and megestrol 40 mg/mL suspension, 20 mL once daily for appetite stimulation...These types of encephalopathies have been seen in patients with cancer and have thus been termed paraneoplastic. The presence of anti-VGKC antibodies on RS's paraneoplastic panel directed the inpatient medical oncology team toward a paraneoplastic neurologic disorder (PND) as the most likely diagnosis.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Oct 9, 2018   
    P2,  N=4, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Sep 2019 --> Oct 2020 | Trial primary completion date: Sep 2018 --> Oct 2019
  • ||||||||||  Megace (megestrol) / BMS, SOBI
    Review, Journal:  The Evolving Approach to Management of Cancer Cachexia. (Pubmed Central) -  Jul 27, 2018   
    Appetite stimulants, such as megestrol acetate and glucocorticoids, have been shown to increase appetite and weight; however, single pharmaceutical interventions alone for cachexia do not result in meaningful functional outcomes...Use of an appetite stimulant could be considered for patients who exhibit decreased appetite. Treatment with an anti-inflammatory agent should be considered for patients with elevated C-reactive protein, and hormonal alterations resulting from anti-cachexia therapy should be thoughtfully addressed.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial primary completion date, Metastases:  Randomized Control Trial (RCT) of Early Palliative Care for HCC (clinicaltrials.gov) -  May 30, 2018   
    P=N/A,  N=72, Not yet recruiting, 
    Treatment with an anti-inflammatory agent should be considered for patients with elevated C-reactive protein, and hormonal alterations resulting from anti-cachexia therapy should be thoughtfully addressed. Trial primary completion date: Sep 2019 --> Sep 2020
  • ||||||||||  megestrol / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  Randomized Control Trial (RCT) of Early Palliative Care for HCC (clinicaltrials.gov) -  Feb 20, 2018   
    P=N/A,  N=72, Not yet recruiting, 
    Trial primary completion date: Sep 2019 --> Sep 2020 Initiation date: Sep 2017 --> Apr 2018 | Trial primary completion date: Sep 2018 --> Sep 2019 | Trial completion date: Sep 2019 --> Sep 2020
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Megace (megestrol) / BMS, SOBI
    Review, Journal:  New therapies for advanced, recurrent, and metastatic endometrial cancers. (Pubmed Central) -  Dec 9, 2017   
    The National Cancer Institute (NCI) and others are now focusing their efforts on the design of scientifically rational targeted therapy and immunotherapy trials for specific molecular phenotypes of endometrial cancer. This is essential for the advancement of cancer care for women, which is threatened by a severe enrollment decline of approximately 80% for gynecologic oncology clinical trials.
  • ||||||||||  megestrol / Generic mfg.
    Journal:  Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases. (Pubmed Central) -  Oct 25, 2017   
    Recruiting --> Completed •Progestins can produce clinical benefit in a subset of women with metastatic endometrial cancer.•Corticosteroid-related effects of megestrol can cause morbidity over the long term.•Norethindrone is a progestin without corticosteroid side effects.•A switch from megestrol to norethindrone decreased toxicity with continued benefit.•A clinical trial of norethindrone for this population of patients would be welcome.
  • ||||||||||  megestrol / Generic mfg.
    Enrollment open:  Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia (clinicaltrials.gov) -  Oct 24, 2017   
    P2/3,  N=120, Recruiting, 
    •Progestins can produce clinical benefit in a subset of women with metastatic endometrial cancer.•Corticosteroid-related effects of megestrol can cause morbidity over the long term.•Norethindrone is a progestin without corticosteroid side effects.•A switch from megestrol to norethindrone decreased toxicity with continued benefit.•A clinical trial of norethindrone for this population of patients would be welcome. Active, not recruiting --> Recruiting
  • ||||||||||  megestrol / Generic mfg., Relivar (dronabinol buccal) - Sumitomo Dainippon, Tetra Bio / Pharma, dronabinol oral / Generic mfg.
    Biomarker, Journal:  Cancer Cachexia: Beyond Weight Loss. (Pubmed Central) -  Oct 5, 2017   
    Consequently, oncologists have a role in ensuring that these resources are available to their patients. In addition, in light of the promising investigational agents, it remains imperative to refer patients with cachexia to clinical trials so that available options can be expanded to effectively treat this pervasive problem.
  • ||||||||||  everolimus / Generic mfg.
    Trial primary completion date, Metastases:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Oct 2, 2017   
    P2,  N=4, Active, not recruiting, 
    In addition, in light of the promising investigational agents, it remains imperative to refer patients with cachexia to clinical trials so that available options can be expanded to effectively treat this pervasive problem. Trial primary completion date: Sep 2017 --> Sep 2018
  • ||||||||||  megestrol / Generic mfg.
    Trial initiation date, Metastases:  Randomized Control Trial (RCT) of Early Palliative Care for HCC (clinicaltrials.gov) -  May 24, 2017   
    P=N/A,  N=72, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Sep 2015 --> Sep 2017
  • ||||||||||  phenytoin / Generic mfg., megestrol / Generic mfg.
    Trial completion:  Phenytoin for Memory Impairment Secondary to Megestrol (clinicaltrials.gov) -  Dec 29, 2016   
    P0,  N=22, Completed, 
    Trial primary completion date: Apr 2017 --> Aug 2017 Recruiting --> Completed
  • ||||||||||  metformin / Generic mfg.
    New P2 trial:  Mirena (clinicaltrials.gov) -  Dec 13, 2016   
    P2,  N=120, Enrolling by invitation, 
  • ||||||||||  everolimus / Generic mfg.
    Enrollment closed, Enrollment change, Trial primary completion date, Metastases:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Sep 26, 2016   
    P2,  N=4, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=38 --> 4 | Trial primary completion date: Feb 2017 --> Sep 2017
  • ||||||||||  everolimus / Generic mfg.
    Enrollment change, Metastases:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Mar 24, 2016   
    P2,  N=38, Recruiting, 
    Active, not recruiting --> Completed N=70 --> 38